Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology

(2019) Manuel Scimeca et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer

(2019) Kathleen N. Moore et al.   GYNECOLOGIC ONCOLOGY

The Crucial Role of the WNT System in Bone Remodelling

(2018) D Grigorie   Acta Endocrinologica-Bucharest

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

(2017) David Miles et al.   EUROPEAN JOURNAL OF CANCER

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

(2017) Marcus M. Fischer et al.   Science Advances

An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control

(2014) H. Clevers et al.   SCIENCE

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA